Fig. 1

MCT-1 is a prognostic marker of human breast carcinoma. (a) Immunohistology was used to analyze MCT-1 protein levels in normal tissues, DCIS and IDC of the breast. T: tumor. D: Duct. Scale bars, 50 μm. (b) MCT-1 protein levels in breast cancers were classified based on pathologic stages, molecular subtypes and biomarkers. The results were evaluated from 6 to 8 randomly chosen imaging fields per sample. The Fisher exact probability test of independence was used to calculate the clinical significance. (c and d) MCF-10A acini morphogenesis was studied on a Matrigel matrix culture for 12 days followed by EGFR Ab (green) and DNA (blue) staining. (e and f) EGFR expression, Src/Stat3 activation and EMT molecules were analyzed in MCF-10A and MDA-MB-231 cells without (control) or with MCT-1 induction (MCT-1). (g) EMT molecules and EGFR/Src/Stat3 activation were assessed in MDA-MB-231 (IV2–3) without (scramble) or with MCT-1 knockdown (shMCT-1#3). (h) Time-lapse imaging recorded movements of MDA-MB-231 (IV2–3) (scramble vs. shMCT-1#2 and #3). Different blots were normalized with β-actin and then the relative protein amounts were compared with the corresponding controls. One-way ANOVA with a post hoc two-tailed t-test was used to calculate the statistical significance of the cell migration assays (n = 12). (*** p < 0.001)